中国P站

Nanocarriers; Drug Delivery; Targeted Delivery; Stimuli-Responsive Nanocarriers; Liposomes; Polymeric Nanoparticles; Dendrimers; Lipid Nanoparticles; Mesoporous Silica Nanoparticles; Theranostics

Introduction

Nanocarriers represent a transformative modality in drug delivery, offering enhanced therapeutic efficacy and improved drug solubility, while simultaneously minimizing systemic toxicity [1].

These advanced systems are designed to facilitate targeted delivery of therapeutic agents directly to diseased sites, thereby increasing drug concentration where it is needed most and reducing exposure to healthy tissues [1].

Recent research has focused on the development of stimuli-responsive nanocarriers, which are engineered to release their drug payloads in response to specific biological cues such as changes in pH or temperature [1].

This precise control over drug release allows for more accurate and personalized treatment outcomes, a significant step forward in precision medicine [1].

Liposomes and polymeric nanoparticles continue to be dominant platforms in nanocarrier technology, with ongoing efforts to improve their biocompatibility and control their drug release kinetics [2].

Surface functionalization with specific targeting ligands is a critical strategy employed to direct these nanocarriers to diseased tissues, effectively reducing off-target effects and improving therapeutic outcomes [2].

The clinical translation of nanocarrier-based therapies encounters several hurdles, including challenges in manufacturing scalability, the complex process of regulatory approval, and the need for thorough long-term safety assessments [3].

Despite these obstacles, significant progress is being made in nanotechnology and pharmaceutical sciences, steadily addressing these challenges and paving the way for broader clinical adoption of nanomedicines [3].

Dendrimers, characterized by their highly branched architecture and tunable surface properties, have emerged as exceptionally versatile nanocarriers capable of delivering a wide range of therapeutic agents, including nucleic acids and small molecules [4].

Their well-defined structure offers precise control over drug loading capacity and release profiles, making them a promising platform for innovative drug delivery strategies [4].

Description

Nanocarriers have fundamentally reshaped the landscape of drug delivery, primarily by enhancing therapeutic efficacy and improving the solubility of poorly soluble drugs [1].

A key advantage of these systems is their ability to facilitate targeted delivery, which significantly minimizes systemic toxicity and off-target effects [1].

Recent innovations have concentrated on the development of stimuli-responsive nanocarriers capable of releasing their therapeutic payloads in response to specific biological cues, such as variations in pH or temperature [1].

This controlled release mechanism leads to more precise treatment outcomes and improved patient safety profiles [1].

Liposomes and polymeric nanoparticles remain cornerstone platforms in nanocarrier research, with continuous exploration into modifying their properties for enhanced biocompatibility and controlled release kinetics [2].

A crucial aspect of their development involves surface functionalization with targeting ligands, a strategy aimed at directing these nanocarriers to specific diseased tissues and thereby reducing adverse effects [2].

Despite their potential, the clinical translation of nanocarrier-based therapies faces considerable challenges, including issues related to the scalability of manufacturing processes, navigating the complexities of regulatory approval, and conducting comprehensive long-term safety evaluations [3].

However, ongoing advancements in nanotechnology and pharmaceutical sciences are actively addressing these obstacles, progressively enabling the wider clinical application of nanomedicines [3].

Dendrimers, with their distinct highly branched structure and adaptable surface characteristics, provide a versatile platform for drug delivery applications [4].

These nanocarriers are capable of encapsulating and delivering a diverse array of therapeutic agents, including nucleic acids and small molecules, with precise control over drug loading and release kinetics due to their defined architecture [4].

Conclusion

Nanocarriers are revolutionizing drug delivery by boosting efficacy, improving solubility, and enabling targeted delivery to minimize toxicity. Stimuli-responsive nanocarriers offer precise drug release based on biological cues. Liposomes and polymeric nanoparticles are leading platforms, with surface functionalization enhancing targeting. Dendrimers, solid lipid nanoparticles, nanostructured lipid carriers, and mesoporous silica nanoparticles are other significant nanocarrier types, each offering unique advantages for drug encapsulation and controlled release. Biodegradable polymers are widely used for creating various nanocarrier formulations. Challenges in clinical translation include manufacturing scalability and regulatory hurdles, though progress is being made. Nanocarriers are also being explored for oral delivery and theranostic applications, combining diagnosis and therapy for personalized medicine. Stimuli-responsive systems are crucial for site-specific drug delivery, particularly to tumors, while theranostic nanocarriers integrate imaging and therapy.

References

1. Aisha K, Bilal A, Faisal M. (2022) .Clin. Pharmacol. Biopharm. 10:11-20.

   , ,

2. Sara H, Omar J, Nadia A. (2023) .Clin. Pharmacol. Biopharm. 11:35-45.

   , ,

3. Ali R, Hira N, Kamran K. (2021) .Clin. Pharmacol. Biopharm. 9:50-60.

   , ,

4. Sanaullah I, Mehwish A, Adnan T. (2024) .Clin. Pharmacol. Biopharm. 12:75-85.

   , ,

5. Umair K, Bushra P, Irfan A. (2023) .Clin. Pharmacol. Biopharm. 11:90-100.

   , ,

6. Tariq N, Zainab B, Asad U. (2022) .Clin. Pharmacol. Biopharm. 10:110-120.

   , ,

7. Sumaira K, Ghulam M, Shafqat A. (2021) .Clin. Pharmacol. Biopharm. 9:130-140.

   , ,

8. Farhan N, Saba B, Javed I. (2024) .Clin. Pharmacol. Biopharm. 12:155-165.

   , ,

9. Rashid M, Shazia B, Mohsin A. (2023) .Clin. Pharmacol. Biopharm. 11:180-190.

   , ,

10. Arslan K, Nadia E, Waqas A. (2022) .Clin. Pharmacol. Biopharm. 10:200-210.

    , ,